Lowering Drug Prices By Once Again Putting Americans First

Listen to the summary

0:00

The Executive Order aims to restore and enhance efforts to reduce prescription drug prices in the U.S., reversing policies of the Biden Administration.
Key accomplishments of the previous administration included:
- Promoting lower prices for prescription drugs through increased access to generics and biosimilars.
- Establishing a pathway for the importation of lower-cost drugs.
- Ensuring government discounts reach patients rather than middlemen.
- Introducing price transparency rules for patients, doctors, and employers.
- Capping insulin copayments for Medicare beneficiaries.
- Proposing innovative payment mechanisms to manage drug prices.
The Biden Administration's actions included:
- The Inflation Reduction Act aimed at addressing Medicare drug prices, but faced criticism for complexity and lower than expected savings.
- Imposing earlier price controls on small molecule drugs, which is seen as jeopardizing innovation.
The Order outlines several directives:
- Within 60 days, HHS Secretary to propose guidance for the Medicare Drug Price Negotiation Program for the years 2026-2028.
- Within 180 days, recommendations on stabilizing and reducing Medicare Part D premiums.
- Modifications to align treatment of small molecule drugs with biological products to prevent distortion of investments.
- Develop and implement a payment model to achieve better value for high-cost drugs.
- Conduct a survey of hospital acquisition costs for outpatient drugs to align Medicare payments with those costs.
- Ensure manufacturers provide accurate Medicaid drug rebates and promote innovation in payment methodologies.
- Grants for health centers to make insulin and injectable epinephrine available at discounted prices for low-income individuals.
- Recommendations to promote a competitive and efficient pharmaceutical value chain.
- Recommendations to accelerate approvals for generics and improve the over-the-counter classification process for certain drugs.
- Streamline importation processes for States to obtain approval without sacrificing safety.
- Evaluate regulations to prevent cost shifts from physician offices to hospital outpatient settings.
- Propose regulations to improve employer transparency regarding pharmacy benefit managers.
- Conduct public listening sessions to recommend measures reducing anti-competitive behavior in the pharmaceutical industry.
The order reaffirms the authority of executive agencies and is subject to applicable laws and appropriations.